The Hartford Insurance Group (HIG) Earnings Date & Reports

Key Takeaways

• The Hartford posted third-quarter core earnings of $3.50 per diluted share, topping the consensus estimate of $3.17 by about 10%.
• Total revenue of $7.22 billion was roughly flat year over year and came in slightly below the $7.41 billion consensus estimate.
• Net income available to common stockholders rose 23% to $1.32 billion, or $4.82 per diluted share, boosted by a reinsurance commutation gain.
• The insurer raised its quarterly dividend by 12% to $0.67 per share and returned $638 million to shareholders during the quarter.
• Business Insurance written premiums grew 6%, while consolidated net investment income climbed 13% to $850 million before tax.
• For additional detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for HIG.
• Explore Trending AI Robots to discover AI-driven trading strategies and automated market insights.

Earnings Context and Why It Matters

The Hartford Financial Services Group's third-quarter report matters because it tests how well a diversified property and casualty (P&C) insurer is navigating an increasingly competitive pricing environment. The company has leaned on its commercial lines business to drive growth, while its personal auto segment faces ongoing pressure on new business. Investors are also watching how management deploys capital after a major reinsurance commutation and the announced sale of Hartford Funds. With premiums growing steadily and investment income benefiting from higher reinvestment rates, this quarter offers a clear read on underwriting discipline, reserve strength, and the durability of shareholder returns.

Reported Results

For the third quarter of 2026, The Hartford reported core earnings of $956 million, or $3.50 per diluted share, down from $1.02 billion, or $3.59 per diluted share, in the prior-year period. The result exceeded the consensus estimate of $3.17 per share by roughly 10%. Total revenue came in at $7.22 billion, essentially flat year over year and below the approximately $7.41 billion consensus.

On a GAAP (Generally Accepted Accounting Principles) basis, net income available to common stockholders was $1.32 billion, or $4.82 per diluted share, up 23% from $1.07 billion a year earlier. The quarter was shaped by a reinsurance commutation agreement with National Indemnity Company (NICO, a Berkshire Hathaway subsidiary), which terminated The Hartford's asbestos and environmental adverse development cover. The company received $1.12 billion in cash proceeds and recognized a $497 million pre-tax gain, which was excluded from core earnings.

Business Insurance core earnings rose to $731 million from $723 million, with written premiums up 6%. Personal Insurance core earnings fell to $105 million from $143 million, and Group Benefits core earnings declined to $120 million from $149 million. Consolidated net investment income increased 13% to $850 million before tax. The company raised its quarterly dividend by 12% to $0.67 per share.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like HIG, it can surface relevant opportunities and signals across the broader insurance and financials landscape.

Market Reaction and Investor Sentiment

The market response to The Hartford's results was relatively muted, with shares holding near $136 shortly after the report. The earnings beat on core EPS was offset by a modest top-line miss, and the large GAAP profit boost was widely understood to be driven by the one-time reinsurance commutation rather than recurring operations. Investors also weighed a slight deterioration in the Business Insurance underlying combined ratio, which crossed above 90%, against a stabilizing personal lines segment. The 12% dividend increase and continued share repurchases signaled management confidence in capital strength, even as the competitive backdrop and reserve considerations drew attention.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Business Insurance can sustain mid-single-digit written premium growth without further erosion in its underlying combined ratio, which measures underwriting profitability. Expense discipline and favorable reserve development have supported results, but higher catastrophe losses and competitive pricing in commercial lines remain key variables.

The personal lines turnaround is another area to monitor. Renewal pricing increases in automobile and homeowners have outpaced loss cost trends, yet new business growth in auto remains constrained. Continued improvement in the personal auto underlying loss ratio would support a more balanced earnings mix.

Finally, the commutation of the asbestos and environmental coverage re-exposes The Hartford to legacy tail risk ahead of its fourth-quarter reserve review, while the Hartford Funds sale removes a source of fee income. Capital deployment, including the enlarged buyback authorization and dividend growth, will remain central to the investment case as management redeploys proceeds and investment income benefits from higher reinvestment rates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations